Nifty
:
22147.00
Sensex
:
73088.33
151.15 (0.69%)
599.34 (0.83%)
Nifty
Sensex
:
:
22147.00
73088.33
151.15 (0.69%)
599.34 (0.83%)

Cipla Ltd.

Pharmaceuticals & Drugs - Global

Rating :
61/99

BSE: 500087 | NSE: CIPLA

NSE BSE
1345.75
19-Apr-2024
  • Open
  • High
  • Low
  • Previous Close
  •  1347.00
  •  1357.70
  •  1335.00
  •  1347.30
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  1173025
  •  15792.25
  •  1519.00
  •  896.30

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 108,622.88
  • 29.29
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 108,116.76
  • 0.63%
  • 4.19

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 33.47%
  • 0.54%
  • 14.33%
  • FII
  • DII
  • Others
  • 25.73%
  • 22.21%
  • 3.72%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 8.38
  • 6.82
  • 5.90

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 8.87
  • 11.71
  • 3.27

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 7.19
  • 12.67
  • 5.07

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 32.08
  • 30.34
  • 30.63

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.54
  • 3.59
  • 3.91

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 16.32
  • 15.38
  • 16.30

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 23
Dec 22
Var%
Sep 23
Sep 22
Var%
Jun 23
Jun 22
Var%
Mar 23
Mar 22
Var%
Net Sales
6,603.81
5,810.09
13.66%
6,678.15
5,828.54
14.58%
6,328.89
5,375.19
17.74%
5,739.30
5,260.33
9.11%
Expenses
4,856.28
4,402.54
10.31%
4,944.40
4,526.21
9.24%
4,834.98
4,231.84
14.25%
4,565.56
4,510.61
1.22%
EBITDA
1,747.53
1,407.55
24.15%
1,733.75
1,302.33
33.13%
1,493.91
1,143.35
30.66%
1,173.74
749.72
56.56%
EBIDTM
26.46%
24.23%
25.96%
22.34%
23.60%
21.27%
20.45%
14.25%
Other Income
184.63
114.44
61.33%
176.32
122.95
43.41%
136.29
103.43
31.77%
134.63
64.02
110.29%
Interest
30.10
31.82
-5.41%
25.80
25.55
0.98%
16.39
17.81
-7.97%
34.36
18.10
89.83%
Depreciation
233.43
272.11
-14.21%
290.04
299.37
-3.12%
239.21
254.41
-5.97%
346.22
290.31
19.26%
PBT
1,473.81
1,218.06
21.00%
1,594.23
1,100.36
44.88%
1,374.60
974.56
41.05%
745.37
447.83
66.44%
Tax
405.30
410.01
-1.15%
438.41
302.60
44.88%
378.02
268.00
41.05%
222.25
71.11
212.54%
PAT
1,068.51
808.05
32.23%
1,155.82
797.76
44.88%
996.58
706.56
41.05%
523.12
376.72
38.86%
PATM
16.18%
13.91%
17.31%
13.69%
15.75%
13.14%
9.11%
7.16%
EPS
13.08
9.92
31.85%
14.01
9.78
43.25%
12.33
8.51
44.89%
6.51
4.49
44.99%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Net Sales
25,350.15
22,753.12
21,763.34
19,159.59
17,131.99
16,362.41
15,155.71
14,394.29
13,594.89
11,345.44
10,173.39
Net Sales Growth
13.81%
4.55%
13.59%
11.84%
4.70%
7.96%
5.29%
5.88%
19.83%
11.52%
 
Cost Of Goods Sold
8,832.82
8,252.28
8,495.60
7,351.89
5,991.42
5,784.49
5,438.42
5,317.12
5,089.86
4,270.63
3,874.83
Gross Profit
16,517.33
14,500.84
13,267.74
11,807.70
11,140.57
10,577.92
9,717.29
9,077.17
8,505.03
7,074.81
6,298.56
GP Margin
65.16%
63.73%
60.96%
61.63%
65.03%
64.65%
64.12%
63.06%
62.56%
62.36%
61.91%
Total Expenditure
19,201.22
17,762.83
17,251.38
14,910.94
13,951.18
13,494.26
12,702.32
11,918.50
11,115.22
9,183.74
8,040.34
Power & Fuel Cost
-
353.61
331.03
308.26
327.43
335.11
298.82
251.73
245.92
228.28
218.63
% Of Sales
-
1.55%
1.52%
1.61%
1.91%
2.05%
1.97%
1.75%
1.81%
2.01%
2.15%
Employee Cost
-
3,830.08
3,529.91
3,251.83
3,027.01
2,856.53
2,690.10
2,633.82
2,434.01
1,967.72
1,542.96
% Of Sales
-
16.83%
16.22%
16.97%
17.67%
17.46%
17.75%
18.30%
17.90%
17.34%
15.17%
Manufacturing Exp.
-
1,589.90
1,453.22
1,206.33
1,372.03
1,284.94
1,220.67
1,192.77
1,023.49
737.11
644.42
% Of Sales
-
6.99%
6.68%
6.30%
8.01%
7.85%
8.05%
8.29%
7.53%
6.50%
6.33%
General & Admin Exp.
-
1,423.23
1,206.07
986.01
1,289.13
1,096.50
1,002.43
868.31
845.89
743.46
638.08
% Of Sales
-
6.26%
5.54%
5.15%
7.52%
6.70%
6.61%
6.03%
6.22%
6.55%
6.27%
Selling & Distn. Exp.
-
1,694.30
1,670.00
1,298.62
1,252.04
1,281.29
1,082.90
1,009.21
818.76
738.87
680.32
% Of Sales
-
7.45%
7.67%
6.78%
7.31%
7.83%
7.15%
7.01%
6.02%
6.51%
6.69%
Miscellaneous Exp.
-
619.43
565.55
508.00
692.12
855.40
968.98
645.54
657.29
497.67
680.32
% Of Sales
-
2.72%
2.60%
2.65%
4.04%
5.23%
6.39%
4.48%
4.83%
4.39%
4.34%
EBITDA
6,148.93
4,990.29
4,511.96
4,248.65
3,180.81
2,868.15
2,453.39
2,475.79
2,479.67
2,161.70
2,133.05
EBITDA Margin
24.26%
21.93%
20.73%
22.18%
18.57%
17.53%
16.19%
17.20%
18.24%
19.05%
20.97%
Other Income
631.87
512.13
321.73
269.77
369.38
476.57
357.65
228.69
208.21
165.55
265.37
Interest
106.65
109.54
106.35
160.70
197.36
168.43
114.23
159.38
206.63
168.29
145.74
Depreciation
1,108.90
1,172.11
1,051.95
1,067.66
1,174.65
1,097.15
949.83
1,322.93
754.22
504.71
372.64
PBT
5,188.01
4,220.77
3,675.39
3,290.06
2,178.18
2,079.14
1,746.98
1,222.17
1,727.03
1,654.25
1,880.04
Tax
1,443.98
1,202.86
933.80
888.76
631.20
569.53
250.11
179.76
331.59
400.03
463.38
Tax Rate
27.83%
29.79%
26.73%
27.01%
28.98%
27.39%
14.98%
14.71%
19.20%
24.18%
24.65%
PAT
3,744.03
2,804.51
2,529.57
2,417.66
1,593.98
1,544.87
1,413.31
1,013.38
1,372.01
1,206.07
1,400.73
PAT before Minority Interest
3,708.83
2,835.49
2,559.47
2,401.30
1,546.98
1,509.61
1,419.35
1,042.41
1,395.44
1,254.22
1,416.66
Minority Interest
-35.20
-30.98
-29.90
16.36
47.00
35.26
-6.04
-29.03
-23.43
-48.15
-15.93
PAT Margin
14.77%
12.33%
11.62%
12.62%
9.30%
9.44%
9.33%
7.04%
10.09%
10.63%
13.77%
PAT Growth
39.23%
10.87%
4.63%
51.67%
3.18%
9.31%
39.46%
-26.14%
13.76%
-13.90%
 
EPS
46.47
34.81
31.40
30.01
19.78
19.17
17.54
12.58
17.03
14.97
17.39

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Shareholder's Funds
23,407.78
20,841.69
18,326.53
15,763.00
15,012.28
14,229.19
12,543.66
11,516.22
10,801.49
10,050.35
Share Capital
161.43
161.36
161.29
161.25
161.14
161.02
160.90
160.68
160.59
160.58
Total Reserves
23,184.53
20,636.35
18,123.15
15,548.70
14,794.10
14,001.91
12,320.74
11,266.12
10,557.74
9,868.12
Non-Current Liabilities
183.53
621.70
1,660.47
2,972.37
4,646.15
4,259.05
4,514.99
1,407.13
2,417.66
2,028.05
Secured Loans
332.46
376.20
355.32
304.74
47.70
0.00
0.00
207.00
287.09
317.44
Unsecured Loans
-332.46
40.04
847.43
2,064.54
3,782.37
3,662.11
3,645.36
14.88
22.19
0.43
Long Term Provisions
102.16
100.22
116.17
133.27
121.41
137.92
140.52
144.68
1,783.17
1,368.64
Current Liabilities
5,033.27
4,912.87
4,591.14
4,393.14
3,771.51
3,832.22
3,388.91
7,776.05
3,881.13
2,563.58
Trade Payables
2,457.05
2,508.10
2,066.82
2,281.81
1,947.99
2,119.12
1,586.30
1,475.82
1,452.06
979.53
Other Current Liabilities
1,085.07
769.81
1,093.21
706.65
541.86
647.04
908.95
1,006.14
654.55
408.67
Short Term Borrowings
187.90
393.34
334.73
447.15
486.16
435.87
467.23
4,969.67
1,392.48
910.47
Short Term Provisions
1,303.25
1,241.62
1,096.38
957.53
795.50
630.19
426.43
324.42
382.04
264.91
Total Liabilities
28,930.34
26,651.95
24,837.20
23,422.79
23,761.91
22,672.90
20,885.79
21,049.49
17,280.76
14,691.56
Net Block
9,100.65
9,621.91
9,393.77
9,558.59
9,546.51
9,949.14
9,508.16
9,368.32
6,829.64
6,496.47
Gross Block
17,204.76
16,968.35
15,647.05
14,913.62
13,790.31
12,960.01
11,370.70
10,167.62
9,561.55
8,676.27
Accumulated Depreciation
7,994.72
7,310.84
6,216.82
5,309.30
4,233.78
3,010.87
1,609.71
799.30
2,731.91
2,179.80
Non Current Assets
11,731.79
11,924.75
11,656.17
11,716.61
11,335.28
11,858.80
12,082.23
12,208.26
9,689.47
9,039.59
Capital Work in Progress
1,093.30
766.18
968.89
824.53
676.18
981.33
1,682.98
2,060.87
580.90
441.84
Non Current Investment
572.52
355.63
545.43
578.80
490.20
157.66
137.36
176.35
249.76
397.14
Long Term Loans & Adv.
845.11
736.39
645.57
677.08
455.57
514.96
543.67
426.18
1,860.29
1,545.25
Other Non Current Assets
60.38
383.22
102.51
77.61
166.82
255.71
210.06
176.54
168.88
158.89
Current Assets
16,805.06
14,710.83
13,181.03
11,706.18
12,426.63
10,814.10
8,803.56
8,841.23
7,591.29
5,651.97
Current Investments
3,089.86
2,194.97
2,286.37
1,016.52
2,125.79
1,102.21
837.39
582.34
390.02
311.43
Inventories
5,156.43
5,350.24
4,669.18
4,377.60
3,964.83
4,044.70
3,519.72
3,808.05
3,780.62
2,895.26
Sundry Debtors
4,057.00
3,424.44
3,445.68
3,891.31
4,150.72
3,102.45
2,582.17
2,356.27
1,997.72
1,638.89
Cash & Bank
1,564.62
1,928.48
1,401.23
1,003.91
618.81
965.61
638.27
871.40
564.26
175.76
Other Current Assets
2,937.15
305.56
347.54
442.02
1,566.48
1,599.13
1,226.01
1,223.17
858.67
630.63
Short Term Loans & Adv.
2,563.16
1,507.14
1,031.03
974.82
1,150.95
1,118.93
807.84
780.03
713.07
595.13
Net Current Assets
11,771.79
9,797.96
8,589.89
7,313.04
8,655.12
6,981.88
5,414.65
1,065.18
3,710.16
3,088.39
Total Assets
28,536.85
26,635.58
24,837.20
23,422.79
23,761.91
22,672.90
20,885.79
21,049.49
17,280.76
14,691.56

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Cash From Operating Activity
3,237.65
3,325.90
3,755.20
3,068.45
1,691.14
1,462.76
2,381.76
1,740.81
1,173.43
1,563.31
PBT
4,220.77
3,675.39
3,290.06
2,178.18
2,079.14
1,669.46
1,222.17
1,727.03
1,654.25
1,880.04
Adjustment
878.19
967.47
1,130.91
1,365.53
1,268.77
1,293.82
1,374.42
950.85
630.05
552.80
Changes in Working Capital
-559.42
-177.46
371.66
372.99
-1,063.54
-778.48
235.44
-429.38
-718.61
-561.26
Cash after chg. in Working capital
4,539.54
4,465.40
4,792.63
3,916.70
2,284.37
2,184.80
2,832.03
2,248.50
1,565.69
1,871.58
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-1,301.89
-1,139.50
-1,037.43
-848.25
-593.23
-722.04
-450.27
-507.69
-392.26
-308.27
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-2,388.51
-1,871.88
-2,387.18
104.04
-1,668.68
-854.01
-1,310.21
-4,522.63
-941.15
-1,249.86
Net Fixed Assets
-637.57
-321.93
-437.48
-450.41
-173.16
-509.84
-889.04
1,487.25
-534.38
-437.26
Net Investments
-935.67
-1,124.06
-2,533.43
-1,439.15
-1,239.74
-351.09
-30.10
164.99
-833.97
-985.31
Others
-815.27
-425.89
583.73
1,993.60
-255.78
6.92
-391.07
-6,174.87
427.20
172.71
Cash from Financing Activity
-958.29
-1,599.79
-1,239.51
-2,948.82
-348.72
-385.48
-1,325.68
3,104.06
164.78
-265.63
Net Cash Inflow / Outflow
-109.15
-145.77
128.51
223.67
-326.26
223.27
-254.13
322.24
397.06
47.82
Opening Cash & Equivalents
658.11
790.43
649.13
508.36
853.47
610.35
858.15
545.84
175.76
143.01
Closing Cash & Equivalent
561.33
658.11
790.43
742.38
508.36
853.46
610.35
858.15
564.26
175.76

Financial Ratios

Consolidated /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Book Value (Rs.)
289.24
257.78
226.73
194.85
185.62
175.92
155.15
142.23
133.38
124.79
ROA
10.19%
9.94%
9.95%
6.56%
6.50%
6.52%
4.97%
7.28%
7.85%
10.49%
ROE
12.85%
13.10%
14.13%
10.09%
10.37%
10.65%
8.72%
12.61%
12.10%
14.89%
ROCE
18.19%
17.24%
17.85%
12.53%
11.94%
10.20%
8.28%
13.24%
15.33%
19.05%
Fixed Asset Turnover
1.81
1.82
1.85
1.89
1.79
1.25
1.36
1.40
1.26
1.47
Receivable days
44.13
42.19
47.44
54.10
55.36
68.17
61.60
57.62
57.94
58.66
Inventory Days
61.98
61.53
58.49
56.12
61.13
90.71
91.41
100.43
106.36
93.68
Payable days
109.80
98.28
107.95
128.84
59.02
57.37
46.96
51.51
52.17
44.93
Cash Conversion Cycle
-3.69
5.44
-2.02
-18.63
57.47
101.50
106.05
106.55
112.14
107.41
Total Debt/Equity
0.02
0.04
0.10
0.18
0.29
0.29
0.33
0.46
0.16
0.12
Interest Cover
37.87
33.85
21.47
12.04
13.34
15.61
8.67
9.36
10.83
13.90

Annual Reports:

FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014

News Update:


  • Cipla's arm signs agreement for acquisition of business undertaking from Ivia Beaute
    16th Apr 2024, 09:20 AM

    This strategic move is aligned with Cipla’s focus on enhancing its consumer healthcare and wellness portfolio

    Read More
  • USFDA concludes routine cGMP inspection at Cipla’s manufacturing facility in Patalganga
    5th Apr 2024, 09:24 AM

    On conclusion of the inspection, the company has received 6 inspectional observations in Form 483

    Read More
  • Cipla partners with Sanofi India
    27th Mar 2024, 10:46 AM

    Cipla will be responsible for the distribution of Sanofi India’s six CNS brands including Frisium

    Read More
  • Cipla’s arm completes sale of entire shareholding in Wellthy
    7th Mar 2024, 09:25 AM

    The consideration received from such sale is Rs 59.71 lakh

    Read More
  • Cipla transfers Generics Business Undertaking to Cipla Pharma and Life Sciences
    2nd Mar 2024, 09:33 AM

    The company had received approval from board of directors to transfer Generics Business Undertaking

    Read More
  • Cipla secures approval to market novel antibiotic plazomicin in India
    27th Feb 2024, 16:57 PM

    Plazomicin's introduction in India underscores Cipla's proactive response to the urgent global challenge of antimicrobial resistance

    Read More
  • Cipla ties up with CSIR-CDRI
    16th Feb 2024, 10:41 AM

    The collaboration aims to leverage the combined expertise and resources of both organisations to develop a safe and efficacious drug for fungal keratitis

    Read More
  • Cipla’s arm completes acquisition of 100% equity stake in Actor Pharma
    8th Feb 2024, 09:20 AM

    Accordingly, Actor will now be a wholly owned step-down subsidiary of the Company

    Read More
  • Cipla acquires additional stake in GoApptiv
    3rd Feb 2024, 10:25 AM

    Accordingly, Cipla will now hold 22.99% stake on a fully diluted basis in GoApptiv

    Read More
  • Cipla’s arms incorporate wholly owned subsidiary in Mexico
    23rd Jan 2024, 15:12 PM

    Mexicip is incorporated with an objective of sale and distribution of pharmaceutical drugs in Mexico

    Read More
  • Cipla reports 32% rise in Q3 consolidated net profit
    23rd Jan 2024, 14:26 PM

    Total consolidated income of the company increased by 14.58% at Rs 6788.44 crore for Q3FY24

    Read More
  • Cipla - Quarterly Results
    22nd Jan 2024, 18:49 PM

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.